Salvage cryotherapy in patients undergoing endoscopic eradication therapy for complicated Barrett’s esophagus

Abstract

Background and study aims Some patients with dysplastic Barrett’s esophagus (BE) experience suboptimal response to radiofrequency ablation (RFA), endoscopic mucosal resection (EMR), or the combination. Cryotherapy has been used as salvage therapy in these patients, but outcomes data are limited. We aimed to assess clinical outcomes among a large cohort of patients with dysplastic BE whose condition had failed to respond to RFA and/or EMR.

Patients and methods This was a retrospective cohort study of consecutive cases of dysplastic BE or intramucosal carcinoma (IMC) treated with salvage cryotherapy at a tertiary-care academic medical center. The primary goal of cryotherapy treatment was eradication of all neoplasia. The secondary goal was eradication of all intestinal metaplasia. The proportion of patients undergoing salvage cryotherapy who achieved complete eradication of dysplasia (CE-D) and metaplasia (CE-IM), as well as the time to CE-D and CE-IM were calculated.

Results Over a 12-year period, 46 patients received salvage cryotherapy. All patients underwent RFA prior to cryotherapy, either at our center or prior to referral, and 50 % of patients underwent EMR. A majority of patients (54 %) had high-grade dysplasia (HGD) at referral, while 33 % had low-grade dysplasia (LGD), and 13 % had IMC. Overall, 38 patients (83 %) reached CE-D and 21 (46 %) reached CE-IM. Median time to CE-D was 18 months, median number of total interventions (RFA, cryotherapy, and EMR) was five, and median number of cryotherapy sessions was two.

Conclusion Salvage cryotherapy appears safe and effective for treating BE that is refractory to RFA and/or EMR.

• References

• 1 Bollschweiler E, Wolfgarten E, Gutschow C. et al. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001; 92: 549-555
• 2 Blot WJ, Devesa SS, Kneller RW. et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287-1289
• 3 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29
• 4 Singh S, Manickam P, Amin AV. et al. Incidence of esophageal adenocarcinoma in Barrettʼs esophagus with low-grade dysplasia: a systematic review and meta-analysis. Gastrointest Endosc 2014; 79: 897-909 e4 quiz 83 e1, 83 e3
• 5 Sharma P, Falk GW, Weston AP. et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrettʼs esophagus. Clin Gastroenterol Hepatol 2006; 4: 566-572
• 6 Verbeek RE, van Oijen MG, ten Kate FJ. et al. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrettʼs esophagus: a Dutch population-based study. Am J Gastroenterol 2012; 107: 534-542
• 7 Bennett C, Moayyedi P, Corley DA. et al. BOB CAT: A large-scale review and Delphi consensus for management of barrettʼs esophagus with no dysplasia, indefinite for, or low-grade dysplasia. Am J Gastroenterol 2015; 110: 662-682 quiz 83
• 8 Evans JA, Early DS. Committee ASoP. et al. The role of endoscopy in Barrettʼs esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc 2012; 76: 1087-1094
• 9 Fitzgerald RC, di Pietro M, Ragunath K. et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrettʼs oesophagus. Gut 2014; 63: 7-42
• 10 Shaheen NJ, Falk GW, Iyer PG. et al. ACG Clinical Guideline: Diagnosis and management of Barrettʼs esophagus. Am J Gastroenterol 2016; 111: 30-50 quiz 1
• 11 Wani S, Rubenstein JH, Vieth M. et al. Diagnosis and management of low-grade dysplasia in Barrettʼs esophagus: expert review from the Clinical Practice Updates Committee of the American Gastroenterological Association. Gastroenterology 2016; 151: 822-835
• 12 Phoa KN, van Vilsteren FG, Weusten BL. et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA 2014; 311: 1209-1217
• 13 Shaheen NJ, Sharma P, Overholt BF. et al. Radiofrequency ablation in Barrettʼs esophagus with dysplasia. N Engl J Med 2009; 360: 2277-2288
• 14 Chadwick G, Groene O, Markar SR. et al. Systematic review comparing radiofrequency ablation and complete endoscopic resection in treating dysplastic Barrettʼs esophagus: a critical assessment of histologic outcomes and adverse events. Gastrointest Endosc 2014; 79: 718-731 e3
• 15 Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrettʼs Esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 1245-1255
• 16 Canto MI, Shin EJ, Khashab MA. et al. Safety and efficacy of carbon dioxide cryotherapy for treatment of neoplastic Barrettʼs esophagus. Endoscopy 2015; 47: 582-591
• 17 Gosain S, Mercer K, Twaddell WS. et al. Liquid nitrogen spray cryotherapy in Barrettʼs esophagus with high-grade dysplasia: long-term results. Gastrointest Endosc 2013; 78: 260-265
• 18 Shaheen NJ, Greenwald BD, Peery AF. et al. Safety and efficacy of endoscopic spray cryotherapy for Barrettʼs esophagus with high-grade dysplasia. Gastrointest Endosc 2010; 71: 680-685
• 19 Visrodia K, Zakko L, Singh S. et al. Cryotherapy for persistent Barrettʼs esophagus after radiofrequency ablation: a systematic review and meta-analysis. Gastrointest Endosc 2018; 87: 1396-1404.e1
• 20 Levine DS, Haggitt RC, Blount PL. et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrettʼs esophagus. Gastroenterology 1993; 105: 40-50
• 21 Qumseya BJ, Wani S, Desai M. et al. Adverse events after radiofrequency ablation in patients with Barrettʼs esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016; 14: 1086-1095 e6
• 22 Pasricha PJ, Hill S, Wadwa KS. et al. Endoscopic cryotherapy: experimental results and first clinical use. Gastrointest Endosc 1999; 49: 627-631
• 23 Dumot JA, Vargo 2nd JJ. et al. An open-label, prospective trial of cryospray ablation for Barrettʼs esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc 2009; 70: 635-644
• 24 Ramay FH, Cui Q, Greenwald BD. Outcomes after liquid nitrogen spray cryotherapy in Barrettʼs esophagus-associated high-grade dysplasia and intramucosal adenocarcinoma: 5-year follow-up. Gastrointest Endosc 2017; 86: 626-632
• 25 Ghorbani S, Tsai FC, Greenwald BD. et al. Safety and efficacy of endoscopic spray cryotherapy for Barrettʼs dysplasia: results of the National Cryospray Registry. Dis Esophagus 2016; 29: 241-247
• 26 Weusten BL, Bergman JJ. Cryoablation for managing Barrettʼs esophagus refractory to radiofrequency ablation? Donʼt embrace the cold too soon!. Gastrointest Endosc 2015; 82: 449-451
• 27 Manner H, Rabenstein T, Pech O. et al. Ablation of residual Barrettʼs epithelium after endoscopic resection: a randomized long-term follow-up study of argon plasma coagulation vs. surveillance (APE study). Endoscopy 2014; 46: 6-12
• 28 Shaheen NJ, Overholt BF, Sampliner RE. et al. Durability of radiofrequency ablation in Barrettʼs esophagus with dysplasia. Gastroenterology 2011; 141: 460-468